PAWC
CCCC icon

P.A.W. Capital’s C4 Therapeutics CCCC Stock Holding History

P.A.W. Capital’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-40,000
Closed -$1.79M – 61
2021
Q3 		$1.79M Sell
40,000
-10,000
-20% -$428K 1.59% 19
2021
Q2 		$1.89M Hold
50,000
– – 1.59% 21
2021
Q1 		$1.85M Buy
50,000
+10,000
+25% +$398K 1.63% 19
2020
Q4 		$1.32M Buy
+40,000
New +$1.16M 1.17% 25

Other funds holding CCCC

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

P.A.W. Capital's CCCC Position: Q4 2021 in Review

P.A.W. Capital sold out of C4 Therapeutics (CCCC) in Q4 2021, closing a stake of 40,000 shares — an estimated $1.79M sold.

P.A.W. Capital first reported a position in CCCC in Q4 2020 and held it in 4 quarters. The position peaked at $1.89M in Q2 2021. 119 funds tracked by Wall St. Rank hold CCCC as of Q4 2021.

  • P.A.W. Capital reported no remaining C4 Therapeutics position as of Q4 2021 after selling out during the quarter.
  • P.A.W. Capital sold 40,000 C4 Therapeutics shares in Q4 2021, an estimated $1.79M.
  • P.A.W. Capital first reported a position in C4 Therapeutics in Q4 2020 and held it in 4 quarters.
  • P.A.W. Capital's C4 Therapeutics position peaked at $1.89M in Q2 2021.
  • 119 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2021.

Based on P.A.W. Capital's 13F filing for Q4 2021, filed 10 Feb 2022.